Closed-loop control performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) system in a feasibility study

Journal of Diabetes Science and Technology

Volumn 8, Issue 1, 2014, Pages 35-42

  Finan, Daniel A ^a   McCann Jr , Thomas W ^a   Mackowiak, Linda ^a   Dassau, Eyal ^b,c   Patek, Stephen D ^d   Kovatchev, Boris P ^d   Doyle III, Francis J ^b,c   Zisser, Howard ^b,c   Anhalt, Henry ^a   Venugopalan, Ramakrishna ^a  

^a Animas Corporation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Algorithm; Artificial pancreas; Closed loop control; Model predictive control; Type 1 diabetes

Indexed keywords

CARBOHYDRATE; GLUCOSE; INSULIN;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CLINICAL RESEARCH; CLOSED LOOP CONTROL ALGORITHM; CONTINUOUS GLUCOSE MONITOR; DIABETIC KETOACIDOSIS; DRUG DELIVERY DEVICE; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIA HYPERGLYCEMIA MINIMIZER SYSTEM; INFUSION PUMP; INFUSION RATE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MALE; MEAL; MONITOR; SKIN BLEEDING; SKIN BRUISING;

EID: 84900535462     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813511730     Document Type: Article

References (17)

1. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther. 2009;11(suppl 1):S113-S119.
2. Breton M, Farret A, Bruttomesso D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes. 2012;61(9):2230-2237.
3. Dassau E, Zisser H, Harvey RA, et al. Clinical evaluation of a personalized artificial pancreas. Diabetes Care. 2013;36(4):801-809.
4. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375(9716):743-751.
5. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012;35(11):2148-2155.
6. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006;55(12):3344-3350.
7. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011;60(11):2672-2682.
8. U.S. Department of Health of Human Services. Guidance for industry and Food and Drug Administration staff. The content of investigational device exemption (IDE) and premarket approval (PMA) applications for artificial pancreas device systems. November 9, 2012. Available at: http://www.fda.gov/ downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ UCM259305.pdf. Accessed May 22, 2013.
9. Kovatchev BP, Breton M, Man CD, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol. 2009;3(1):44-55.
10. Patek SD, Bequette BW, Breton M, et al. In silico preclinical trials: methodology and engineering guide to closed-loop control in type 1 diabetes mellitus. J Diabetes Sci Technol. 2009;3(2):269-282.
11. Venugopalan R, Finan DA, McCann Jr TW, et al. Performance metrics of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a closed-loop feasibility study. Diabetes. 2012;61(suppl 1):A235.
12. Mackowiak L, Finan DA, McCann Jr TW, Venugopalan R, Zisser H, Anhalt H. Feasibility study assessing Hypoglycemia-Hyperglycemia Minimizer (HHM) System in patients with type 1 diabetes (T1DM) in a clinical research center (CRC). Diabetes. 2012;61(suppl 1):A233.
13. Dassau E, Zisser H, Palerm CC, Buckingham BA, Jovanovic L, Doyle FJ 3rd. Modular artificial beta-cell system: a prototype for clinical research. J Diabetes Sci Technol. 2008;2(5):863-872.
14. Grosman B, Dassau E, Zisser HC, Jovanovic L, Doyle FJ 3rd. Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events. J Diabetes Sci Technol. 2010;4(4):961-975.
15. Hughes CS, Patek SD, Breton MD, Kovatchev BP. Hypoglycemia prevention via pump attenuation and red-yellow-green "traffic" lights using continuous glucose monitoring and insulin pump data. J Diabetes Sci Technol. 2010;4(5):1146-1155.
16. Nimri R, Atlas E, Ajzensztejn M, Miller S, Oron T, Phillip M. Feasibility study of automated overnight closed-loop glucose control under MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project. Diabetes Technol Ther. 2012;14(8):728-735.
17. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368(9):824-833.